ArticleTherapeutic advances in hematology2026
Efficacy and safety of different TPO-RAs combined with cyclosporine in the treatment of NSAA.
Article in Therapeutic advances in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: TPO receptor agonists (TPO-RAs) have significantly improved the treatment outcomes of patients with aplastic anemia. Currently, three small-molecule TPO-RAs (eltrombopag, hetrombopag, and avatrombopag) are available for clinical use and work well. Objectives: This article aims to compare the efficacy and safety of these TPO-RAs in treating non-severe aplastic anemia (NSAA). Design: This was a single-center, retrospective observational cohort study. Methods: A retrospective analysis was performed to assess the efficacy and side effects of cyclosporine A (CsA) combined with different TPO - RAs in 67 NSAA patients. Patients were divided into three groups according to the type of TPO-RA received: eltrombopag, hetrombopag, or avatrombopag. The overall response rate (ORR) was evaluated at 3 months and 6 months after treatment initiation. Adverse events, including liver impairment, infection, and death, were recorded and compared among the three groups. Results: In total,the 3-month overall response rate (ORR) of CsA combined with TPO-RAs was 71.6%, the 6-month ORR was 82.1%. The ORRs among eltrombopag, hetrombopag, and avatrombopag groups were no statistically significant difference at the 3-month (P=0.334) or 6-month (P=0.776). Due to the pre-screening of patients with underlying liver conditions, the occurrence of side effects including new liver impairment, infection and death, showed no significant differences among the three groups. High level of absolute reticulocyte count at enrollment and adequate initial treatment dose of TPO-RAs are independent factors for better efficacy at 6 months. Old age (P=0.034) and infection(P=0.000) were the independent factors affecting the duration of hospitalization. Conclusions: This study shows that eltrombopag, hetrombopag, and avatrombopag combined with CsA have comparable efficacy in the treatment of NSAA. Identifying patients at high risk for liver injury before treatment and initiating avatrombopag therapy represents a viable clinical treatment option for NSAA patients with pre-existing liver injury. Similar to SAA, NSAA patients should also be initiated with an adequate dose of TPO-RAs therapy. Elderly patients and those with concurrent infections are at higher risk of mortality, prolonged hospitalizations, and require more clinical attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.